Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy

Haemophilia

Volumn 13, Issue 1, 2007, Pages 46-50

  Field, J J ^a   Fenske, T S ^b   Blinder, M A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Autoantibody; Coagulopathy; Haemophilia; High titre; Inhibitors; Rituximab

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLOPHOSPHAMIDE; INSULIN; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CASE REPORT; DEATH; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; ECCHYMOSIS; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INJECTION SITE BLEEDING; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; THERAPY RESISTANCE; TREATMENT REFUSAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BLOOD COAGULATION FACTOR INHIBITORS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; TIME FACTORS; TREATMENT FAILURE; VINCRISTINE;

EID: 33845741137     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01342.x     Document Type: Article

References (22)

1. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
2. Margolius A Jr, Jackson DP, Ratnoff OD. Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine (Baltimore) 1961; 40: 145-202.
3. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-3.
4. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997; 78: 1463-7.
5. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
6. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121: 21-35.
7. Wiestner A, Weksler B, Schechter G. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2003; 101: 3754.
8. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
9. Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: Fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003; 101: 3753-4 (author reply 3754-37).
10. Lian EC, Larcarda AF, Chiu AY. Combination immunosuppression therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-8.
11. Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired haemophilia. Haematologica 2000; 85 (Suppl.): 64-8.
12. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
13. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
14. Abdallah A, Coghlan DW, Duncan EM, Chunilal SD, Lloyd JV. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost 2005; 3: 2589-90.
15. Jy W, Gagliano-DeCesare T, Kett DH et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol 2003; 109: 206-8.
16. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: Management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-15.
17. Aggarwal A, Grewal R, Green RJ et al. Rituximab for autoimmune haemophilia: A proposed treatment algorithm. Haemophilia 2005; 11: 13-9.
18. Low BG, Cohen AJ. Complete remission in high-titer factor VIII inhibitor after rituximab therapy. Blood 2003; 102: 101b.
19. Maruscak M, Cohan B, Aghakhanian L, Ucar K. Rituximab in the treatment of factor VIII inhibitor. Blood 2005; 106: 97b.
20. Karwal MW, Schluete AJ, Zenk DW, Davis RT. Treatment of acquired factor VIII deficiency with rituximab. Blood 2000; 96: 84b.
21. Kasper CK, Aledort LM, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869.
22. Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. CD 20: A target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 2005; 4: 526-31.